СARIPAZIM

Trade name:  Caripazim

International non-patented name:-

Dosage form:

Lyophilized powder for solution for external use

Composition of 1 vial:

Active substance

Papaya Dry Milk-Juice (Latex exsicco Papayaeae) - 350 pe Activity If necessary

Inactive substance

Lactose (Lactose Monohydrate) - up to 350 pe activity

Description:

White-yellowish lyophilized powder or porous mass with a faint specific odor.

Pharmacotherapeutic group:

Proteolytic agent of plant origin

ATC code: [D03B]

Pharmacological features:

External proteolytic agent. It removes necrotic tissues and  viscous secretion, dilutes exudates and  blood clots. Similar in action to chymotripsin and trypsin.

Pharmacokinetics:

When used externally, the drug is not absorbed and has no systemic effects on the body.

Therapeutic indications:

In surgery - Caripazim is used in the Treatment of third degree burn, to interfere with scab formation and clear the granulation tissue of wounds from necrotic suppurative tissue debris;

In Nevrology - in the Treatment of vertebral osteochondrosis, various types of intervertebral disc hernia or diskogenic radiculitis, post-traumatic flexion contracture of fingers, keloid [cheloid] cicatrix of various etymology, osteoarthritis of large joints, scapulohumeral periarthritis, cerebral (including optochiazmolic) and vertebral arachnoiditis, neuritis of the facial nerve, tunnel syndromes;

In stomatology - periodontitis, pulpitis, gingivitis, paradontosis, thrush and ulcer necrotic stomatitis.

Dosage and Directions for use:
Caripazim is administered locally in the treatment of burn wound infections, as solutions with concentrations 17.5PU/ml, 35 PU/ml, 70 PU/ml depending upon scab thickness. Solution is to be prepared immediately before usage, dissolved in 0.5% aqueous solution of novocaine or natrium chloride isotonic solution. Absorbent paper wetted with the said solution is put on the burn surface area, and then covered by moistureproof bandage. Simultaneously solution is applied to 30% of the body area. Bandage is changed daily or twice a day, removing loose distal necrotic tissues. Treatment cours lasts for 4-12 days.
For the treatment of the abovementioned pathologies of musculoskeletal [locomotor] system: keloid [cheloid] cicatrix, neuritis and so on, Caripazim is administered using electrophoretic method. 
In stomatology Caripazim is applied to wash tooth root channels with Caripazim solution. Contents of a bottle is dissolved in 5-10 ml distilled water or physiological solution. For the treatment of chronic Periodontitis washing tooth root channels and in-channel electrophoresis is applied (3-5 sessions) with 1-2% Caripazim solution and wetted tampon is left for 3-4 days. For the treatment of Gingivitis, Paradontosis, traumatic erosion and ulcers Caripazim application is applied for 15-20 minutes (4-10 procedures). 
The Medication is used for in-patient and out-patient treatment.

Side effects and Special precautions:
Caripazim may cause an allergic reaction. Antihistamine therapy is given in case of hypersensitivity expressed in the form of itching activities and increased temperature.

Contraindications:

Increased individual sensitivity to the drug; Pregnancy, lactation; Caripazim should not be administered subcutaneously, intramuscularly or intravenously; Caripazim should not be used in cases of acute inflammation, as well as in the case of sequestration of the disc herniation and sequestration of the spinal canal (foramenal location).

No overdose has been identified

Interaction with other medicinal products:

Interaction of clinical significance with other medicinal products has not been established.

Special instructions:

Avoid children; The drug does not adversely affect the ability to drive and use machines; The effect of tobacco  and  alcohol on the action of the drug during the treatment period has not been established.

 Release form:

Primary packaging. 350 pe lyophilized powder for solution for external use in a 10 ml glass vial, covered with a rubber stopper and lined with aluminum foil. Label the vial.

Secondary packaging. Each vial with instructions is placed in a cardboard box..

Storage instructions:
Store at a dry place at +2 + 8°C; protect from light. 

Shelf life:

2 years. Do not use the drug after the expiration date and in case of a defect detected by visual inspection.

* Use of caripazim by electrophoresis method

By electrophoresis, caripazim is injected only from the positive pole.

• Caripazim electrophoresis in cases of osteochondrosis and discogenic sciatica in the spine:

Treatment is course - 3 courses (1 course 20-30 procedures). A 1-2 day break between procedures is allowed. Repeat courses after 30-60 days.

Immediately before the procedure, 5-10 ml of physiological solution and 1-2 drops of dimexid are inserted into the caripazim vial. The obtained solution is applied to the filter paper placed on the electrode diapers, the dimensions of the diaper are: 10 cm x 15 cm or 15 cm x 20 cm.

Diaper layout options:

Along:

A) Caripazim in the neck area (+)

Euphyllin in the waist area (-)

B) Caripazim in the neck area (+)

Euphyllin in the shoulder area (-)

C) Caripazim in the neck area (+)

Euphyllin with double-sided electrode on both shoulder (-)

D) caripazim in the waist area (+)

Euphyllin at the point of exit of the sciatic nerve (-)

(Posterior surface of thigh)

E) Caripazim in the waist area  (+)

Euphyllin with double-sided electrode in the thigh area  (-)

Transversely:

F) Caripazim in the waist area  (+)

Euphyllin in the abdomen (-).

Diaper temperature 37-39 ° C (checked with water thermometer). Power output is 10-15 mA (should be increased gradually).

Exposure time from 10 to 20 minutes (should be increased gradually).

Adherence to the given parameters is essential; Otherwise the effectiveness of the drug is sharply reduced.

After the procedure, the skin at the injection site should be rinsed with warm soapy water.

Simultaneous infut of caripazim and lithium chloride (3% solution) by electrophoresis is also possible. In this variant the drugs are placed on the same diapers, but the preparations must be soaked in filter papers separately. The input conditions are the same, but lithium should not be used under Voltaren treatment.

• Caripazim electrophoresis in keloid scars area:

A) Caripazim directly on scars (+)

Euphyllin or potassium iodide on the anti-surface e.g. Transversely (-);

B) Caripazim directly on scars (+)

Euphyllin - 15-20 cm away from the first layer (-).

• Caripazim electrophoresis in some forms of facial neuritis:

    Power strength from 1 to 5 milliamperes.

    Caripazim in the form of a Berganie face mask (+)

    Euphyllin in the intercostal area or opposite shoulder (-).

• Caripazim electrophoresis for the treatment of cerebral arachnoiditis (including optochemical):

Caripazim endonasally (+)

Euphyllin in the upper part of the thoracic spine (-).

 Mode of dispensing:

Pharmaceutical product group III, dispensed without a prescription.

Manufacturer:

LEPL TSMU Iovel Kutateladze Institute of Pharmacochemistry

Address: Georgia, Tbilisi 0159, p. Sarajishvili st. №36

Phone: 253-14-94, 252-19-04

Email: ikip@tsmu.edu

Website:  www.ikip.tsmu.edu